NOTCH1 pathway activation contributes to the pathogenesis of over 60% of T-cell acute lymphoblastic leukemia (T-ALL). While Notch is thought to exert the majority of its effects through ...

Notch Therapeutics is making “significant ... including Allogene-partnered induced-pluripotent-stem-cell-derived T cells. It’s also working on a CD19- and CD20-focused CAR therapy, among ...

Vancouver, BC, February 10, 2025-- (T-Net)-- Notch Therapeutics issued a statement recently indicating that the company is taking steps to preserve cash and explore alternative paths forward after ...

Kuick Research Report Highlights Ongoing Developments In Molecular Switches Application Therapeutic Targets & Drug Delivery ...